Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers

Breast Cancer Research and Treatment
Takahiro WatanabeYasuo Miyoshi

Abstract

The therapeutic effect of systemic treatment for breast cancer (BC) generally depends on its intrinsic subtypes. In addition, tumor infiltrating lymphocytes (TILs) are considered to be an independent factor for tumor shrinkage and disease prognosis. High TILs at baseline or after primary systemic chemotherapy are reported to be associated with better survival in triple-negative or human epithelial growth factor receptor 2 (HER2)-positive BCs. However, the prognostic value of TILs in estrogen receptor (ER)-positive and HER2-negative (ER+/HER2-) BC is still controversial. We assessed TIL score (low, intermediate, and high) before and after primary systemic chemotherapy in every subtype of BC, and compared the clinical outcomes. Biopsy specimens of 47 triple-negative, 58 HER2+ and 91 ER+/HER2- BCs were used to assess TILs before treatment. To assess TILs after treatment, we examined residual invasive carcinoma in surgically resected samples of 28 triple-negative, 30 HER2+ and 80 ER+/HER2- BCs. A high TIL score in triple-negative BC before treatment resulted in a significantly higher proportion of pathological complete response (pCR). In contrast, ER+/HER2- BC exhibited fewer instances of pCR than other subtypes. Although not stati...Continue Reading

References

Jan 1, 1992·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S AaltomaaK Syrjänen
Aug 30, 2000·Nature·Charles M PerouD Botstein
Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·T SørlieA L Børresen-Dale
Mar 23, 2004·Annual Review of Immunology·Gavin P DunnRobert D Schreiber
Apr 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Manfred KaufmannGunter von Minckwitz
Apr 18, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lisa A CareyCharles M Perou
Nov 18, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carsten DenkertGunter von Minckwitz
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Oct 9, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio C WolffCollege of American Pathologists
Jan 10, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M V DieciF Andre
Feb 1, 2014·The Lancet Oncology·Giampaolo Bianchini, Luca Gianni
Mar 13, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Sherene LoiChristos Sotiriou
Jul 30, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S AdamsS Badve
Sep 13, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Roberto SalgadoInternational TILs Working Group 2014
Nov 2, 2014·Breast Cancer Research and Treatment·Ezzeldin M IbrahimGhieth A Kazkaz
Nov 30, 2014·Breast Cancer Research : BCR·Elena García-MartínezFrancisco Ayala de la Peña
Jan 7, 2015·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
May 6, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A S CoatesPanel Members
Sep 9, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Akira I Hida, Yasuyo Ohi
Oct 31, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sherene LoiJustin M Balko
May 27, 2017·Polish Journal of Pathology : Official Journal of the Polish Society of Pathologists·Joanna HusznoElżbieta Nowara
Mar 1, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M V DieciF Andre

Citations

Feb 13, 2019·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Jiahui HuangKunwei Shen
Feb 25, 2021·Laboratory Investigation; a Journal of Technical Methods and Pathology·Andrea WalensBenjamin C Calhoun
Mar 6, 2021·Critical Reviews in Oncology/hematology·Rosalba TorrisiArmando Santoro

Related Concepts

HER2delta16 protein, human
Antineoplastic Agents
Biopsy
Breast
Mammary Neoplasms, Human
Mastectomy
Estrogen Nuclear Receptor
Retrospective Studies
Lymphocytes, Tumor-Infiltrating
Mammary Ductal Carcinoma

Related Feeds

Carcinoma, Ductal

Ductal carcinoma is a malignant neoplasm involving the ductal systems of any of a number of organs, such as the mammary glands, pancreas, prostate or lacrimal gland. Discover the latest research on ductal carcinoma here.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.